Health and economic impact of rotavirus vaccination in GAVI-eligible countries by Kim, Sun-Young et al.
Kim et al. BMC Public Health 2010, 10:253
http://www.biomedcentral.com/1471-2458/10/253
Open Access RESEARCH ARTICLE
© 2010 Kim et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons At-
tribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any
medium, provided the original work is properly cited.
Research article Health and economic impact of rotavirus 
vaccination in GAVI-eligible countries
Sun-Young Kim*1,2, Steve Sweet1, David Slichter1,2 and Sue J Goldie1,2
Abstract
Background: Rotavirus infection is responsible for about 500,000 deaths annually, and the disease burden is 
disproportionately borne by children in low-income countries. Recently the World Health Organization (WHO) has 
released a global recommendation that all countries include infant rotavirus vaccination in their national immunization 
programs. Our objective was to provide information on the expected health, economic and financial consequences of 
rotavirus vaccines in the 72 GAVI support-eligible countries.
Methods: We synthesized population-level data from various sources (primarily from global-level databases) for the 72 
countries eligible for the support by the GAVI Alliance (GAVI-eligible countries) in order to estimate the health and 
economic impact associated with rotavirus vaccination programs. The primary outcome measure was incremental cost 
(in 2005 international dollars [I$]) per disability-adjusted life year (DALY) averted. We also projected the expected 
reduction in rotavirus disease burden and financial resources required associated with a variety of scale-up scenarios.
Results: Under the base-case assumptions (70% coverage), vaccinating one single birth cohort would prevent about 
55% of rotavirus associated deaths in the 72 GAVI-eligible countries. Assuming I$25 per vaccinated child (~$5 per dose), 
the number of countries with the incremental cost per DALY averted less than I$200 was 47. Using the WHO's cost-
effectiveness threshold based on per capita GDP, the vaccines were considered cost-effective in 68 of the 72 countries 
(~94%). A 10-year routine rotavirus vaccination would prevent 0.9-2.8 million rotavirus associated deaths among 
children under age 5 in the poorest parts of the world, depending on vaccine scale-up scenarios. Over the same 
intervention period, rotavirus vaccination programs would also prevent 4.5-13.3 million estimated cases of 
hospitalization and 41-107 million cases of outpatient clinic visits in the same population.
Conclusions: Our findings suggest that rotavirus vaccination would be considered a worthwhile investment for 
improving general development as well as childhood health level in most low-income countries, with a favorable cost-
effectiveness profile even under a vaccine price ($1.5-$5.0 per dose) higher than those of traditional childhood 
vaccines.
Background
While childhood diarrhea can be caused by multiple
pathogens, including both bacteria and viruses, rotavirus
is the most common cause of severe diarrhea leading to
hospitalization or disease-specific death among children
under 5 years of age [1,2]. Responsible for more than 2
million hospitalizations and 500,000 deaths annually (as
of 2004), disease mortality is disproportionately borne by
children in low-income countries in Africa and Asia [3].
Since almost all children are infected by age 5, and
improved hygiene, water and sanitation measures have
had little impact on disease burden, vaccination is consid-
ered among the most promising of strategies to prevent
mortality [2].
Rotavirus has diverse genotypes that vary geographi-
cally and over time [4-6], with clinical manifestations of
infection depending heavily on the patient's age [7]. Rota-
virus is also characterized by frequent reinfection, with
developed natural immunity depending on the number of
prior infections. In the last 5 years, two new oral, live
attenuated rotavirus vaccines, Rotarix®  (GlaxoSmith-
K l i n e )  [ a  t w o - d o s e  m o n o v a l e n t  l i v e  a t t e n u a t e d  h u m a n
rotavirus vaccine] and RotaTeq® (Merck & Co., Inc.) [a
* Correspondence: sykim@hsph.harvard.edu
1 Center for Health Decision Science, Department of Health Policy and 
Management, Harvard School of Public Health, Boston MA, USA
Full list of author information is available at the end of the articleKim et al. BMC Public Health 2010, 10:253
http://www.biomedcentral.com/1471-2458/10/253
Page 2 of 24
three-dose human-bovine reassortant pentavalent rotavi-
rus vaccine], have been licensed and are now available in
many countries [8,9]. In 2005, the World Health Organi-
zation (WHO) Strategic Advisory Group of Experts
(SAGE) on Immunization, recommended the introduc-
tion of these vaccines in Europe, the United States, and
Latin America, on the basis of results of phase III clinical
trials [8]; both vaccines appeared to have partial efficacy
of a similar magnitude as that conferred by a single natu-
ral infection. However, SAGE initially withheld a global
recommendation until clinical trials could show satisfac-
tory efficacy in Africa and Asia [8,9]. Clinical trials of
Rotarix® (completed in 2008) demonstrated a reduction of
rotavirus disease burden in South Africa and Malawi [10].
Based on this newer evidence, in June 2009, SAGE rec-
ommended that all countries include infant rotavirus vac-
cination in their national immunization programs [10].
Especially in light of the Millennium Development
Goal (MDG) 4 of child mortality reduction, there has
been an effort at the global level to accelerate introduc-
tion of rotavirus vaccines in developing countries. How-
ever, in addition to the uncertainties about ultimate
efficacy in Africa and Asia, as well as uncertainties about
the likelihood of uptake, the current vaccines are costly
relative to traditional childhood vaccines. Undoubtedly,
the poorest countries will require financial assistance.
The GAVI Alliance has promised to provide financial
support for rotavirus vaccination programs to developing
countries, and the WHO and its partners have estab-
lished global networks for surveillance of rotavirus, pro-
v i d i n g  v a l u a b l e  d a t a  o n  t h e  b u r d e n  o f  s e v e r e  t y p e s  o f
acute rotavirus gastroenteritis [11]. However, given that
the countries eligible for support from the GAVI Alliance
(GAVI-eligible countries) face numerous challenges, not
the least of which is the need to fund other children's
health initiatives within constrained budgets, countries
are being encouraged to consider the potential health
impact, cost-effectiveness, and financial requirements
carefully, before choosing to prioritize rotavirus vaccines.
The objective of this analysis is to use population-based
data for 72 GAVI-eligible countries and provide informa-
tion on the expected health, economic, and financial con-
sequences of rotavirus vaccines.
Methods
Analytic overview
We synthesized population-level data on demographic
structure, country- or region-specific disease burden,
medical utilization patterns for treating rotavirus dis-
eases, and costs in order to estimate the health and eco-
nomic consequences associated with rotavirus
vaccination programs in the 72 GAVI-eligible countries.
(The data used for our study is openly available upon
request.) Model-projected clinical outcomes include
intermediate health outcomes (e.g., hospitalizations),
deaths averted, years of life saved (YLS), and disability-
adjusted life years (DALYs) averted. The primary out-
come measure for the cost-effectiveness analysis was
incremental cost (expressed in 2005 international dollars
[I$] adjusted for price differences across countries using
purchasing power parity estimates) per DALY averted.
For the base-case we adopted a modified societal per-
spective and discounted future costs and disability-
adjusted and unadjusted life years by 3% annually [12-15].
We have also conducted a cost-effectiveness analysis
from the perspective of local government. Sensitivity
analyses were conducted to explore the influence of both
uncertain parameters and assumptions on results. We
projected the expected reduction in rotavirus disease
burden and budget impact associated with a variety of
scale-up scenarios.
Model
Simulation model of the natural history of rotavirus infection
We have previously described a model of the natural his-
tory of rotavirus infection using TreeAge 2008 software
(Williamstown, MA), which captures details such as the
age-specific risk, probability of asymptomatic cases, rate
of reinfection, correlation between strength of natural
immunity and the total number of previous infections,
and waning of vaccine efficacy [16]. We applied the
model to Vietnam to reevaluate the cost-effectiveness of a
rotavirus vaccination program [16]. We leveraged this
work to develop a series of rotavirus disease models to
explore uncertainties associated with analytic choices
about model structure [17], and conducted corroboration
exercises by comparing projected model outcomes to
those obtained using the companion model described
below.
Excel-based companion model
The companion rotavirus model has been developed to
reflect the main features of rotavirus infection and vacci-
nation, and to project the health and economic conse-
quences at the population level, in settings where data are
limited. The model is constructed as a static cohort simu-
lation model and is programmed using Microsoft® Excel
2003 and Visual Basic for Applications 6.3 (Microsoft
Corporation, Redmond, Washington). The model
employs simplifying assumptions that rely on insights
from more complex natural history models [16,17]. The
upper panel in Figure 1 shows the simplified schematic of
natural history represented in the Excel-based compan-
ion model. Severe cases of rotavirus gastroenteritis are
considered those which are symptomatic and requiring
outpatient clinic visit or hospitalization or those resulting
in disease-specific deaths [18].
The Excel-based companion model is applied to birth
cohorts (born in 2010) in the 72 GAVI-eligible countries.Kim et al. BMC Public Health 2010, 10:253
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Figure 1 Schematic of the companion rotavirus model. Upper panel shows the schematic of the natural history model of rotavirus infection the 
companion model is based on. The model assumes one episode of rotavirus diarrhea at maximum and full protection against subsequent rotavirus 
diarrhea during the first 5 years of life of a vaccinated child. Lower panel presents the schematic of the companion model.
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The model tracks the cohorts up to age 5, incorporating
background mortality and recording population-level
health and cost outcomes with and without vaccination
programs. Combining country-specific or region-specific
data on the incidence of rotavirus deaths, ratios of outpa-
tient visits or hospitalizations to rotavirus deaths, and
serotype distribution, the model generates estimates for
the reduction in rotavirus related events requiring medi-
cal treatments (i.e., outpatient clinic visits and hospital-
izations) or leading to deaths. By applying the estimates
to each country's age-structured population, the model
transforms them into aggregated population health out-
come measures, YL and DALYs (Figure 1, Lower Panel).
DALYs are calculated using the approach recommended
by the Global Burden of Disease (GBD) study [19] but are
not age-weighted (age weight modulating factor K = 0)
[20]. We assumed that the average mean duration of a
diarrheal episode was 7 days and that each episode is
associated with a disability weight of 0.119 [19]. The
model also tracks direct medical and non-medical costs
associated with rotavirus disease events and the costs of
the vaccine program from the societal perspective. The
primary measure for the cost-effectiveness analysis is
expressed as the incremental costs (2005 I$) per DALY
averted. The model is also used to project the financial
costs and disease burden reduction at the population
level for a multi-year rotavirus vaccination program,
varying assumptions to simulate different demand fore-
casting and scale-up scenarios.
Model input and assumptions
Intervention: vaccine types and vaccination schedule
The number of doses (and schedule) recommended by
the vaccine manufacturers are 2 (at 2 and 4 months) for
Rotarix® and 3 (at 2,4, and 6 months) for Rotateq®. Because
this analysis is intended to provide a broad policy over-
view of the expected health and economic outcomes of
rotavirus vaccination, and not to contextualize a detailed
situation of a single specific country, we chose not to dis-
tinguish the two vaccines in terms of dose and schedule
or vaccine efficacy. This decision was based in large part
on the WHO SAGE recommendations and in part based
on published evidence: 1) a 3-dose schedule is recom-
mended in any setting where the two vaccines, Rotarix®
and Rotateq® are interchangeably used [21]; 2) efficacy
data for a rotavirus vaccine obtained in one population
can be extrapolated to other populations if the two popu-
lations belong to the same under 5 mortality category
[10]; and 3) in a phase III Rotarix® trial performed in
Malawi, the overall efficacy against severe rotavirus gas-
troenteritis of a 2-dose schedule (49.2%) showed little dif-
ference compared to the corresponding value with a 3-
dose schedule (49.7%) [10]. To first generate an estimate
of the potential avertable global burden with rotavirus
vaccination, we standardized an initial set of assump-
tions: 1) infants are given 3 doses of a rotavirus vaccine
(Rotarix® or Rotateq®) at ages aligned with each countries
EPI visits (or DTP schedule) (6,10, and 14 weeks or 2,4,
and 6 months of age); 2) coverage is 70%, (purposefully
assumed in order to illustrate differences in country-spe-
cific outcomes related to variations in epidemiology); 3)
vaccine-induced immunity is durable over 5 years with-
out waning; and 4), for both vaccines, side effects are con-
sidered negligible as long as the first and last dose of
either vaccine is given at the recommended age ranges (6-
15 weeks for the first dose and 8 months or 32 weeks for
the last dose) [21]. We then conducted additional analy-
ses using a range of alternative assumptions (e.g., waning
of vaccine-acquired immunity).
Vaccine efficacy
We used two different approaches for estimating vaccine
efficacy. For the base-case analysis, recognizing that dif-
ferences in rotavirus serotype distributions would affect
the overall efficacy against severe types of rotavirus, we
calculated a weighted average of serotype-specific vac-
cine efficacy using the country- or region-specific sero-
type distribution data. Data for rotavirus serotype
distributions were obtained from published epidemiolog-
ical studies. When country-specific data were not avail-
able, region-specific estimates reported by the global
networks for rotavirus surveillance were used [11] (see
Additional file 1 for details).
For a secondary analysis, based on the SAGE recom-
mendation that efficacy data of a rotavirus vaccine can be
extrapolated to other populations that have the same
under 5 child mortality stratum, we divided the GAVI
countries into the three categories (i.e., "high" mortality
for the highest quartile, "intermediate" mortality for the
second highest quartile, and "low" mortality for the low-
est two quartiles [10]). We then extrapolated the pooled
efficacy for a 2- or 3-dose schedule obtained from Malawi
(49.5%) [10] to GAVI-eligible countries that belong to the
"high" child mortality stratum and the corresponding
data from South Africa (76.9%) [10] to the countries that
fall on "intermediate" strata. Currently, there are no cor-
responding efficacy data obtained in low income coun-
tries with "low" under 5 mortality. Rather than using the
data from industrialized countries with "low" under 5
mortality, we conservatively chose to use the data from
South Africa for the low-child mortality GAVI-eligible
countries. Under 5 mortality data to stratify countries for
efficacy data extrapolation were obtained from the WHO
World Health Statistics database [22] (Table 1).
Demographic data and assumptions
For country-specific age-structure that incorporates
background mortality, we used the estimates of popula-
tion size (1-year interval) from UN World Population
Prospects 2006 Revision [23]. Age-specific life expec-Kim et al. BMC Public Health 2010, 10:253
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Table 1: Country-specific profiles of the 72 GAVI-eligible countries
Countrya GNI per capita
(2008 US$)
GAVI grouping 
for co-financingb
DTP3 coverage
(2008)
Under 5 child
mortality (per
1,000 live
births) (2006)
Under 5
rotavirus
mortality (per
100000 children
<5) (2004)
Percentage of
death due to
diarrhea among
children under
5 (2000)
AFR D
Angola 3,450 4 81% 260 389 19.1
Benin 690 1 93% 148 182 17.1
Burkina Faso 480 1 99% 204 256 18.8
Cameroon 1,150 3 84% 149 179 17.3
Chad 530 1 43% 209 266 18.1
Comoros 750 1 81% 68 64 13.6
Ghana 670 2 87% 120 92 12.2
Guinea 390 1 70% 161 188 16.5
Guinea-Bissau 250 1 79% 200 283 18.6
Liberia 170 4 92% 235 331 17.3
Madagascar 410 1 88% 115 141 16.9
Mali 580 1 99% 217 307 18.3
Mauritania 840 1 74% 125 153 16.2
Niger 330 1 89% 253 392 19.8
Nigeria 1,160 2 57% 191 228 15.7
Sao Thome 1,020 1 99% 96 129 16.0
Senegal 970 1 88% 116 158 17.1
Sierra Leone 320 4 87% 269 439 19.7
The Gambia 390 1 96% 114 107 12.2
Togo 400 1 89% 107 134 13.8
AFR E
Burundi 140 4 92% 181 255 18.2
Central African Republic 410 4 51% 174 210 14.7
Congo 1,970 4 89% 126 86 11.2
Cote d'Ivoire 980 4 74% 127 223 14.8
Democratic Republic of 
the Congo
150 4 83% 205 281 18.1
Eritrea 300 4 85% 74 84 15.6
Ethiopia 280 1 81% 123 213 17.3
Kenya 770 2 85% 121 135 16.5
Lesotho 1,080 1 91% 132 25 3.9
Malawi 290 1 91% 120 225 18.1
Mozambique 370 1 80% 138 183 16.5
Rwanda 410 1 97% 160 272 18.5
Tanzania 430 1 84% 118 147 16.8
Uganda 420 1 79% 134 165 17.2
Zambia 950 1 95% 182 227 17.5
Zimbabwe c 2 75% 85 106 12.1
AMR A, B & D
Cuba c 2 99% 7 1 1.3
Guyana 1,420 3 93% 62 119 21.4
Honduras 1,800 3 93% 27 43 12.2
Bolivia 1,460 3 83% 61 66 14.3Kim et al. BMC Public Health 2010, 10:253
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Haiti 660 4 53% 80 133 16.5
Nicaragua 1,080 2 96% 26 30 12.2
EMR D
Afghanistan c 4 85% 257 338 18.9
Djibouti 1,130 3 89% 130 145 16.6
Pakistan 980 2 73% 97 95 14.0
Somalia c 4 31% 145 315 18.7
Sudan 1,130 4 93% 89 79 12.9
Yemen 950 1 87% 100 108 16.1
EUR B & C
Armenia 3,350 3 89% 24 29 10.5
Azerbaijan 3,830 3 95% 89 125 15.3
Georgia 2,470 3 92% 32 42 11.5
Kyrgyzstan 740 2 95% 41 86 14.1
Tajikistan 600 2 86% 68 177 16.4
Uzbekistan 910 2 98% 44 88 14.8
Moldova 1,470 2 95% 19 5 2.0
Ukraine 3,210 3 90% 24 2 1.2
SEAR B & D
Indonesia 2,010 3 77% 34 60 18.3
Korea, Democratic 
Republic
c 2 92% 55 56 18.9
Sri Lanka 1,790 3 98% 13 16 13.5
Timor Leste 2,460 4 79% 55 115 21.9
Bangladesh 520 1 87% 69 89 20.0
Bhutan 1,900 1 96% 70 98 20.9
India 1,070 2 84% 76 102 20.3
Myanmar c 1 85% 104 128 21.1
Nepal 400 1 82% 59 91 20.5
WPR B
Cambodia 600 1 91% 82 226 16.6
Kiribati 2,000 3 82% 64 127 21.9
Lao People Democratic 
Republic
750 1 61% 75 122 15.6
Mongolia 1,680 2 96% 42 67 14.5
Papua New Guinea 1,010 2 52% 73 128 15.3
Solomon Islands 1,180 1 78% 72 45 8.8
Viet Nam 890 2 93% 17 21 10.4
a The six WHO geographical regions are the African Region (AFR), Eastern Mediterranean Region (EMR), Region of the Americas (AMR), European 
Region (EUR), South-East Asian Region (SEAR), and Western Pacific Region (WPR). Categories for mortality rates include very low child, very low 
adult mortality (A), low child, low adult mortality (B), low child, high adult mortality (C), high child, high adult mortality (D), and high child and very 
high adult mortality (E). Combining the two dimensions, we modeled 36 countries from AFR (with 20 in AFR D and 16 in AFR E); 6 countries from 
EMR D; 6 countries from AMR A, B & D; 8 countries from EUR B & C; 9 countries from SEAR B & D; and 7 countries from WPR B.
b The GAVI Alliance new vaccine co-financing policy (which came into effect in 2008) requires GAVI-eligible countries to share new vaccine costs 
at one of four levels depending on the country's ability to pay: (1) Poorest group countries will pay $0.20/dose of the first vaccine and $0.15/dose 
for the 2nd and 3rd vaccines; (2) Intermediate group countries will pay $0.30/dose of the first vaccine and $0.15/dose for the 2nd and 3rd vaccines; (3) 
Least Poor group countries will pay $0.20/dose of the first vaccine and $0.15/dose for the 2nd and 3rd vaccines for the first year, but will increase 
their copayment by 15% annually; and (4) Fragile group countries will pay $0.10/dose of the first vaccine and $0.15/dose for the 2nd and 3rd 
vaccines.
c Data are not available.
Table 1: Country-specific profiles of the 72 GAVI-eligible countries (Continued)Kim et al. BMC Public Health 2010, 10:253
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tancy data (grouped in five-year intervals) for calculating
years of life lost as a component of DALYs were obtained
from WHO life tables (for year 2006) [24]. To facilitate
comparison of the results across regions, for the present
analysis, the 72 GAVI-eligible countries were clustered
into 11 groups according to the WHO classification sys-
tem, which is based on geographical location and mortal-
ity rates (see footnotes to Table 1).
Incidence of rotavirus disease events
We estimated age-specific incidence rates of rotavirus-
associated deaths by applying regional estimates of age
distribution (across ages 0, 1, 2, 3, and 4) of severe rotavi-
rus gastroenteritis cases obtained from published litera-
ture [16,25-28] to the WHO estimates of the country-
s peci f i c  cu m u l a t i v e  n u m be r  o f  r o t a vi rus  d ea t h s  a m o n g
children under 5 years of age [29] (Table 1). Incidence
rates of outpatient visits or hospitalization vary widely
depending on the health care infrastructure and
resources available in a country. Estimates of country-
specific ratios of cumulative incidence of outpatient visits
or hospitalizations to deaths were obtained from pub-
lished literature; when country-specific data were not
available, regional estimates or neighboring countries'
values were used. The age-specific incidence rates for
non-fatal outcomes were then estimated by adjusting
cumulative incidence of each outcome by the same age
distribution data mentioned above.
Costs
Costs included both direct medical costs (vaccination
program costs plus medical treatment costs) and indirect
costs (travel costs and caregivers' time costs). Since the
price of a rotavirus vaccine and program costs to deliver
the vaccine in local settings are not known, we use a com-
posite cost approach to estimate the vaccination program
costs among the direct, medical costs. In doing so, we dis-
tinguish cost items that are tradable (e.g., vaccine wast-
age, insurance and security fees associated with freight
into the country) from those that are typically non-trad-
able (e.g., administration, immunization support and
monitoring/programmatic expenses). We conduct analy-
ses assuming a 3-dose vaccination schedule with total
cost per vaccinated child of I$10 and of I$25, implying
vaccine prices per dose of approximately US$1.50 and
US$5.00 respectively. For a composite cost of I$25 per
vaccinated child, we assume the following breakdown of
the total costs: rotavirus vaccine purchase of US$15.00 (3
doses at US$5.00 each); vaccine wastage of approximately
US$2.65 (~15% of vaccine price); freight and insurance
costs of approximately US$0.90 (~6% of vaccine price);
administrative costs of I$1.50; immunization support
(including cold chain, training, and operational costs) of
I$2.95; and other programmatic costs (including surveil-
lance and monitoring and social mobilization) of I$2.00.
The lower cost of I$10 was derived by assuming 3 doses
of vaccine at US$1.50 each, wastage of approximately
US$0.79, freight and insurance costs of approximately
US$0.27, administrative costs of I$0.50, immunization
support of I$2.00, and programmatic costs of I$1.94. For
both composite cost estimates, we assumed that the costs
reflect any initial start-up cost and that the non-tradable
components (such as administration, immunization sup-
port and other programmatic costs) would reflect incre-
mental costs associated with introducing rotavirus
vaccines into a national immunization programs to vary-
ing extents, depending on countries' health system infra-
structure.
Costs for hospitalization were based on country-spe-
cific data. When data were not available, we based esti-
mates on WHO-CHOICE data for the cost of a bed-day
at a secondary hospital, conservatively assuming one pre-
hospitalization consultation in an outpatient setting, one-
time hospitalization, and an average length of stay of 3
days for hospitalization (see also Additional file 1). Simi-
larly, costs for outpatient visits were based on country-
specific data when available, and, when data were not
available, were based on the use of WHO-CHOICE data
for a 20-minute visit at health center (80% coverage)
assuming one visit per episode. We calculated caregiver's
time for hospitalization or outpatient visit by multiplying
an average length of stay for hospitalization (3 days × 8
hours/day) or an average length of an outpatient visit (6
hours) by an estimated country-specific average hourly
wage. The average hourly wage data for each country
were estimated by analyzing the data from the Labor Sta-
tistics database [30] and the World Development Indica-
tors [31], taking into account unemployment and under-
employment rate and distribution of the main industries
in a country (Additional file 1). We obtained estimates of
average transport costs for a visit to medical facilities
from published studies for some countries and extrapo-
lated the data to countries in the same region for which
country-specific estimates were not available (Additional
file 1).
Cost-effectiveness analysis
For the base-case, we estimated the cost-effectiveness of a
rotavirus program in the 72 GAVI-eligible countries from
the societal perspective, following a single birth cohort
over a 5-year time horizon. The primary outcome mea-
sure of the analysis was incremental cost-effectiveness
ratio (expressed in 2005 I$ per DALY averted). The incre-
mental cost is the sum of vaccination program costs,
averted medical treatment costs for children, and averted
caregivers' time and travel costs. We have also evaluated
the cost-effectiveness of rotavirus vaccination from the
local government perspective, including direct medical
costs only and adjusting vaccine costs using the GAVI's
co-financing scheme for new vaccines [32] (see footnotesKim et al. BMC Public Health 2010, 10:253
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to Table 1 for details). The government savings from the
averted medical treatment costs were calculated by
adjusting the total averted medical costs for the public
sector's percentages of total health expenditure [31].
Sensitivity analysis
In order to explore uncertainties surrounding model pro-
jected outcomes, we performed univariate sensitivity
analyses, varying key parameter values and assumptions
one at a time. For example, in a sensitivity analysis, we
assumed that vaccine efficacy against severe rotavirus
diseases would decline over a 5-year time horizon by
~14% annually, based on 2-year efficacy data obtained
from a published study [33]. We have also conducted
multivariate sensitivity analyses by developing multiple
scenarios based on different combinations of analytic
choices (e.g., discount rate or perspective), efficacy levels,
vaccination program costs, etc.
Budget impact analysis and scale-up scenarios
When considering whether to introduce a new vaccine
into a national immunization program, local policy mak-
ers need information on total cost as well as value for
money, in order to assess the affordability and sustain-
ability of a vaccination program. To provide policymakers
with more practical budgetary information, we con-
ducted a budget impact analysis over a 10-year time hori-
zon (2010-2019) from the perspective of budget holders
(i.e., local governments) [34,35] by extending the base-
case analysis using the same Excel-based model. We first
developed alternative roll-out scenarios (i.e., vaccination
introduced at different coverage levels), in which the year
of rotavirus vaccine introduction, maximum achievable
coverage rate, and years to full coverage were varied
across countries. The financial forecasts are based on the
program cost per child of I$25 (i.e., US$5 per vaccine
dose). We calculated the vaccine costs to local govern-
ments according to the GAVI's co-financing scheme [32]
(Table 1), but used the same composite approach as the
base-case cost-effectiveness analysis in estimating the
incremental costs of delivering rotavirus vaccines. The
financial forecasts were expressed in US$ because bud-
gets are typically expressed in nominal rather than real
terms. Note that the financial requirements are not dis-
counted, based on the published guidelines that discount-
ing is not necessary for budget impact analysis [34,35].
For the base-case roll-out scenario, building upon the
two previous approaches-an explicit 2-Phase scenario
envisioned by Artherly et al. [36] and Wolfson et al.'s
approach [37], we categorized the 72 GAVI-eligible coun-
tries into 10 groups according to each country's national
income level (2008) (Table 1), the most recent year's
DPT3 (the third dose of Diptheria-Pertussis-Tetanus vac-
cine) coverage (Table 1), past history of new vaccine (i.e.,
Hib or HepB vaccines) introduction, and Artherly and
colleagues' demand forecasting results [36]. Table 2 pres-
ents the details of the 10 categories and rotavirus vaccine
demand forecasting for 10 consecutive cohorts being
introduced between 2010-2019 for each country. Follow-
ing the approach used by Wolfson et al. [37], we used
DTP3 coverage from 2008 (the most recent year avail-
able) as a proxy for a full coverage. We also used the past
trends in the coverage of Hib, HepB, and DTP3 to fore-
cast years of first introduction and years to full coverage.
We then assumed that 1) countries in Category 1 roll out
in Year 1 (2010), and countries in Category 2 roll out in
2011, etc., with countries in Category 10 rolling out in
Year 10 (2019). (Note that, because Nicaragua has already
introduced Rotarix®, we use 2006 as their start date.); 2) it
takes 2 or 3 years after implementation to reach full cov-
erage for Category 1, 4 years for Categories 2 and 3, 5
years for Categories 4-6, 6 years for Categories 7-8, and 7
years for Categories 9-10; and 3) once full coverage is
achieved, the coverage level would be maintained (Table
2). We also evaluated alternative, more optimistic roll-out
scenarios by using Wolfson et al.'s original assumptions
a djus t ed wit h t he  m os t  r ec e n t  year 's  da ta  f o r GNI pe r
capita and DTP3 coverage [37] and by assuming a flat
coverage of 70% over a 10-year period.
Results
Model validation
To ensure that the companion population-based model
produced results consistent with our state-transition
model when both were subject to our simplifying
assumptions, we compared projected health outcomes
and cost-effectiveness from the two different models for
Vietnam. While the absolute averted deaths reflects both
epidemiological differences in the incidence and propor-
tion of vaccine-targeted serotypes, the cost-effectiveness
ratios estimated using the two models differ by less than
5% (data not shown). Our previous work [17], which
explored model uncertainty by comparing results from
five different models of the natural history of rotavirus
infection, also reaffirmed that our companion model
yielded results consistent with those from more complex
natural history models. According to the previous analy-
sis [17], within the category of static, deterministic,
aggregate-level models, different choices in model struc-
ture lead to relatively modest differences in the estimated
cost-effectiveness of rotavirus vaccination while interme-
diate "non-severe" epidemiologic outcomes vary more
substantially depending on choices of model structure.
Health outcomes
Under the base-case assumptions (70% coverage, a limit
of one rotavirus disease event per child over the first 5
years of life, and vaccine efficacy against severe rotavirusKim et al. BMC Public Health 2010, 10:253
http://www.biomedcentral.com/1471-2458/10/253
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Table 2: Implied coverage rates for a base-case scale-up scenario (%)
Country Categorya Year 1 Year 2 Year 3 Year 4 Year 5 Year 6 Year 7 Year 8 Year 9 Year 10
2010 2011 2012 2013 2014 2015 2016 2017 2018 2019
AFR D
Angola 10 31.0
Benin 5 15.0 30.6 46.2 61.8 77.4 93.0
Burkina Faso 5 57.0 65.4 73.8 82.2 90.6 99.0
Cameroon 3 53.0 60.8 68.5 76.3 84.0 84.0 84.0 84.0
Chad 8 28.0 30.5 33.0
Comoros 7 27.0 36.0 45.0 54.0
Ghana 6 80.0 81.4 82.8 84.2 85.6
Guinea 8 57.0 59.2 61.3
Guinea-Bissau 9 47.0 51.6
Liberia 5 48.0 56.8 65.6 74.4 83.2 92.0
Madagascar 6 61.0 66.4 71.8 77.2 82.6
Mali 5 54.0 63.0 72.0 81.0 90.0 99.0
Mauritania 8 31.0 38.2 45.3
Niger 9 25.0 34.1
Nigeria 4 41.0 44.2 47.4 50.6 53.8 57.0 57.0
Sao Tome 3 43.0 57.0 71.0 85.0 99.0 99.0 99.0 99.0
Senegal 6 54.0 60.8 67.6 74.4 81.2
Sierra Leone 6 24.0 36.6 49.2 61.8 74.4
The Gambia 5 84.0 86.4 88.8 91.2 93.6 96.0
Togo 6 50.0 57.8 65.6 73.4 81.2
AFR E
Burundi 10 74.0
Central African Republic 10 29.0
Congo 10 33.0
Cote d'Ivoire 4 10.0 22.8 35.6 48.4 61.2 74.0 74.0
Democratic Republic of the 
Congo
10 40.0
Eritrea 6 52.0 58.6 65.2 71.8 78.4
Ethiopia 6 42.0 49.8 57.6 65.4 73.2
Kenya 6 72.0 74.6 77.2 79.8 82.4
Lesotho 3 14.0 33.3 52.5 71.8 91.0 91.0 91.0 91.0
Malawi 5 64.0 69.4 74.8 80.2 85.6 91.0
Mozambique 8 25.0 34.2 43.3
Rwanda 5 88.0 89.8 91.6 93.4 95.2 97.0
Tanzania 7 79.0 79.8 80.7 81.5
Uganda 8 29.0 37.3 45.7
Zambia 5 80.0 83.0 86.0 89.0 92.0 95.0
Zimbabwe 8 9.0 20.0 31.0
AMR A, B & D
Cuba 1 93.0 95.0 97.0 99.0 99.0 99.0 99.0 99.0 99.0 99.0
Guyana 1 89.0 93.0 93.0 93.0 93.0 93.0 93.0 93.0 93.0 93.0
Honduras 1 84.0 93.0 93.0 93.0 93.0 93.0 93.0 93.0 93.0 93.0
Bolivia 1 82.0 83.0 83.0 83.0 83.0 83.0 83.0 83.0 83.0 83.0
Haiti 10 39.0Kim et al. BMC Public Health 2010, 10:253
http://www.biomedcentral.com/1471-2458/10/253
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Nicaragua 1b 96.0 96.0 96.0 96.0 96.0 96.0 96.0 96.0 96.0 96.0
EMR D
Afghanistan 10 31.0
Djibouti 2 46.0 56.8 67.5 78.3 89.0 89.0 89.0 89.0 89.0
Pakistan 4 63.0 65.0 67.0 69.0 71.0 73.0 73.0
Somalia 9 33.0 32.7
Sudan 3 22.0 39.8 57.5 75.3 93.0 93.0 93.0 93.0
Yemen 6 9.0 24.6 40.2 55.8 71.4
EUR B & C
Armenia 1 55.0 66.3 77.7 89.0 89.0 89.0 89.0 89.0 89.0 89.0
Azerbaijan 1 95.0 95.0 95.0 95.0 95.0 95.0 95.0 95.0 95.0 95.0
Georgia 1 55.0 67.3 79.7 92.0 92.0 92.0 92.0 92.0 92.0 92.0
Kyrgyzstan 1 10.0 38.3 66.7 95.0 95.0 95.0 95.0 95.0 95.0 95.0
Tajikistan 1 39.0 54.7 70.3 86.0 86.0 86.0 86.0 86.0 86.0 86.0
Uzbekistan 1 5.0 36.0 67.0 98.0 98.0 98.0 98.0 98.0 98.0 98.0
Moldova 1 81.0 85.7 90.3 95.0 95.0 95.0 95.0 95. 0 95.0 95.0
Ukraine 1 4.0 32.7 61.3 90.0 90.0 90.0 90.0 90.0 90.0 90.0
SEAR B & D
Indonesia 4 42.0 49.0 56.0 63.0 70.0 77.0 77.0
Korea, Democratic 
Republic
10 27.0
Sri Lanka 3 62.0 71.0 80.0 89.0 98.0 98.0 98.0 98.0
Timor Leste 4 57.0 61.4 65.8 70.2 74.6 79.0 79.0
Bangladesh 7 5.0 18.7 32.3 46.0
Bhutan 3 90.0 91.5 93.0 94.5 96.0 96.0 96.0 96.0
India 3 6.0 25.5 45.0 64.5 84.0 84.0 84.0 84.0
Myanmar 7 8.0 20.8 33.7 46.5
Nepal 7 2.0 15.3 28.7 42. 0
WPR B
Cambodia 5 50.0 58.2 66.4 74.6 82.8 91.0
Kiribati 2 36.0 47.5 59.0 70.5 82.0 82.0 82.0 82.0 82.0
Lao People Democratic 
Republic
8 50.0 51.8 53.7
Mongolia 2 95.0 95.3 95.5 95.8 96.0 96.0 96.0 96.0 96.0
Papua New Guinea 4 60.0 58.4 56.8 55.2 53.6 52.0 52.0
Solomon Islands 2 53.0 59.3 65.5 71.8 78.0 78.0 78.0 78.0 78.0
Viet Nam 5 78.0 81.0 84.0 87.0 90.0 93.0
a The profile of each category is as follows: 
Category 1: 13 countries classified by Atherly et al.'s demand forecasting study [36] as "Phase 1" countries that are likely to introduce rotavirus 
vaccines earlier than other countries.
Category 2: Lower middle per capita income ($976-3,705) and introduction of both Hib and HepB vaccines.
Category 3: Lower middle per capita income ($976-3,705), either Hib or HepB vaccine introduction, and high (>80%) to very high (>90%) DTP3 
coverage.
Category 4: Lower middle per capita income ($976-3,705), either Hib or HepB vaccine introduction, and low (<70%) to moderate (>70%) DTP3 
coverage.
Category 5: Low income (<$975), Hib or HepB vaccine introduction, and very high (>90%) DTP3 coverage.
Category 6: Low income (<$975), both Hib and HepB vaccine introduction, and high (>80%) DTP3 coverage.
Category 7: Low income (<$975), either Hib or HepB vaccine introduction, and high (>80%) DTP3 coverage.
Category 8: Low income (<$975), either Hib or HepB vaccine introduction, and low (<70%) to moderate (>70%) DTP3 coverage.
Category 9: Low income (<$975), neither Hib nor HepB vaccine introduction.
Category 10: 8 countries judged by Atherly et al. [36] to be countries that are not likely to introduce rotavirus vaccines.
b Introduced rotavirus vaccine in 2006.
Table 2: Implied coverage rates for a base-case scale-up scenario (%) (Continued)Kim et al. BMC Public Health 2010, 10:253
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cases adjusted for country-specific serotype distribution),
vaccinating one single birth cohort would prevent
approximately 52% (range: 50%-59%) of severe rotavirus
disease events across the 72 GAVI-eligible countries
compared to no vaccination (Table 3). However, the dis-
tribution of the absolute numbers of the reduced rotavi-
rus disease burden would vary across regions or countries
according to the varying levels of risk of rotavirus death.
The number of rotavirus deaths averted per 1,000 vacci-
nated children varied from near 0 (Cuba) to 16 (Sierra
Leone) (Table 3). The upper panel of Figure 2 shows that
more than a half of the absolute global reduction (in
terms of DALYs) would occur in the African region, and
that the South-East Asian Region is another region that
would benefit greatly from rotavirus vaccine introduc-
tion. The lower panel of Figure 2 indicates that the high-
est reduction in burden would be achieved in countries
with a high disease burden (≥200 rotavirus deaths per
100,000 children under 5 years of age) but a similar
reduction would be achieved in countries with a medium
burden (100-200 rotavirus deaths per 100,000 children
under 5 years of age) because reduction in disease burden
also depends heavily on population size and country-spe-
cific vaccine efficacy adjusted for local rotavirus serotype
distributions.
Cost-effectiveness
Table 4 shows the incremental cost-effectiveness ratios of
a rotavirus vaccination program in each of the 72 coun-
tries for the two different estimated total costs per vacci-
nated child of I$10 and I$25, which correspond to the per
dose vaccine costs of US$1.5 and US$5. Assuming I$25
per vaccinated child for the base-case, the number of
countries with the incremental cost per DALY averted
less than I$100 was 23. Among the rest of the countries,
the corresponding ratios of 24 countries fell between
I$100-I$200. It should be noted that the incremental cost
per DALY averted was relatively high in four countries
(Cuba, I$28,440; Moldova, I$4,500; Sri Lanka, I$1,300;
and Ukraine, I$12,160), mainly due to their relatively low
rotavirus mortality (Cuba, 1; Moldova, 5; Sri Lanka, 16;
and Ukraine, 2 per 100,000 children under age 5). Assum-
ing I$10 per vaccinated child, rotavirus infant vaccination
would be cost-saving in 10 countries, and, in another 55
countries, the incremental cost per DALY averted would
be less than I$200. However, in the four countries with
relatively low rotavirus disease burden, the ratios would
still be relatively high, with I$11,330, I$1,760, I$490, and
I$4,820, respectively, for Cuba, Moldova, Sri Lanka, and
Ukraine. Table 4 also presents the cost-effectiveness
results from the local government perspective, in which
the per-child vaccination program costs accrued to local
governments range between I$10.3-I$10.6 (depending on
the level of national income and the history of other new
vaccine introduction) when assuming US$5 per vaccine
dose in the market. The results suggest that, under this
alternative government perspective, rotavirus vaccination
would be considered more cost-effective than for the
base-case societal perspective, presumably due to the
financial support for vaccine purchase from GAVI.
While there is no consensus on a threshold cost-effec-
tiveness ratio under which an intervention is cost-effec-
tive, a useful proxy suggested by WHO to compare
different public health interventions is per capita GDP
[38]. In this context, to facilitate comparison of the cost-
effectiveness of rotavirus vaccines in different settings,
we compared the base-case results with each country's
per capita GDP and found that a rotavirus vaccination
program would be cost-effective in all GAVI countries
except the four with relatively low rotavirus death rates
(Table 4).
Sensitivity analyses
Results were most sensitive to vaccination cost per child,
rotavirus-associated mortality, ratios of hospitalizations
and outpatient visits to deaths, vaccine efficacy against
severe gastroenteritis, and the discount rate. For example,
at a total cost per vaccinated child of I$5, rotavirus vacci-
nation was shown to be cost-saving in 54 countries and
for the rest of the countries (except for Cuba, Moldova,
Sri Lanka, and Ukraine) the incremental cost-effective-
ness ratios ranged between I$1-I$170 per DALY averted.
With a total cost per vaccinated child of I$50, rotavirus
vaccines were not cost-saving in any GAVI-eligible coun-
tries. Results were moderately sensitive to hospitaliza-
tion, outpatient visit costs, and level of vaccine immunity
waning. When we decreased age-specific vaccine efficacy
by ~14% annually over a 5-year time horizon in India, for
instance, the incremental cost per DALY averted (at I$25
per child) increased from I$200 to I$220. The results
were robust to duration of the disease, disability weight
for diarrhea, transportation cost per visit, length of stay
for hospitalization, and time per outpatient visit.
When we used standard age weighting (K = 1) [19]
instead of uniform age weighting (K = 0), outcomes
looked more favorable. For example, using K = 1, the total
numbers of DALYs averted (discounted at 3%) among the
72 GAVI-eligible countries increased to ~8.1 million
(compared to ~7.1 million with K = 0), and the incremen-
tal costs per DALY averted decreased by approximately 9-
13% for each of the GAVI-eligible countries.
We conducted analyses using alternative vaccine effi-
cacy data by following the WHO SAGE recommendation
for efficacy data extrapolation across countries. The aver-
age rotavirus death reduction for the GAVI-eligible coun-
tries was reduced to ~41% (compared to ~52%), since the
average vaccine efficacy against severe rotavirus diseases
was lower using this approach than calculating based onKim et al. BMC Public Health 2010, 10:253
http://www.biomedcentral.com/1471-2458/10/253
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Table 3: Health outcomes of rotavirus vaccination in the GAVI-eligible countries
Country Base-case vaccine efficacy (adjusted for 
serotype distribution)
Vaccine efficacy based on SAGE 
recommendation
Reduction in 
risk of severe 
rotavirus 
disease events
Rotavirus deaths
averted (per
1000 vaccinated
children)
DALYs
averted
Reduction in risk
of severe
rotavirus disease
events
Rotavirus deaths
averted (per
1000 vaccinated
children)
DALYs
averted
AFR D
Angola 55% 14.2 176,385 35% 9.0 111,341
Benin 55% 6.7 42,644 35% 4.2 26,918
Burkina Faso 50% 8.6 92,836 35% 5.9 63,999
Cameroon 54% 6.6 67,042 35% 4.2 42,761
Chad 55% 9.8 76,358 35% 6.2 48,200
Comoros 55% 2.4 1,245 54% 2.3 1,221
Ghana 59% 3.7 44,965 35% 2.2 26,291
Guinea 55% 6.9 43,736 35% 4.3 27,608
Guinea-Bissau 50% 9.5 13,602 35% 6.5 9,366
Liberia 55% 12.1 38,173 35% 7.6 24,096
Madagascar 55% 5.2 68,520 35% 3.3 43,252
Mali 55% 11.1 110,369 35% 7.0 69,669
Mauritania 55% 5.7 10,359 35% 3.6 6,539
Niger 55% 14.4 160,612 35% 9.1 101,384
Nigeria 51% 7.7 733,421 35% 5.3 498,170
Sao Thome 55% 4.7 430 35% 3.0 272
Senegal 55% 5.8 45,473 35% 3.7 28,704
Sierra Leone 55% 15.9 62,305 35% 10.1 39,329
The Gambia 55% 4.0 4,250 35% 2.5 2,682
Togo 55% 5.0 21,192 35% 3.1 13,377
AFR E
Burundi 55% 9.3 67,442 35% 5.8 42,572
Central African Republic 55% 7.7 19,559 35% 4.8 12,346
Congo 55% 3.2 7,180 35% 2.0 4,532
Cote d'Ivoire 51% 7.6 85,210 35% 5.2 57,935
Democratic Republic of the Congo 55% 10.3 541,455 35% 6.5 341,786
Eritrea 55% 3.1 11,263 54% 3.0 11,045
Ethiopia 55% 7.8 443,905 35% 4.9 280,209
Kenya 55% 5.0 132,053 35% 3.1 83,357
Lesotho 55% 0.9 838 35% 0.6 529
Malawi 57% 8.6 81,905 35% 5.2 50,027
Mozambique 55% 6.8 90,101 35% 4.3 56,875
Rwanda 55% 9.9 75,890 35% 6.2 47,905
Tanzania 57% 5.5 146,305 35% 3.4 89,138
Uganda 55% 6.0 153,907 35% 3.8 97,151
Zambia 51% 7.8 56,160 35% 5.3 37,952
Zimbabwe 52% 3.6 21,407 35% 2.4 14,392
AMR A, B & DKim et al. BMC Public Health 2010, 10:253
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Cuba 57% 0.0 63 54% 0.0 60
Guyana 57% 4.8 969 54% 4.6 923
Honduras 57% 1.7 6,710 54% 1.6 6,386
Bolivia 57% 2.6 12,692 54% 2.5 12,080
Haiti 57% 5.2 26,275 35% 3.2 16,098
Nicaragua 57% 1.2 3,384 54% 1.1 3,195
EMR D
Afghanistan 53% 12.5 254,469 35% 8.2 166,606
Djibouti 53% 5.4 2,234 35% 3.5 1,463
Pakistan 53% 3.5 315,915 35% 2.3 206,836
Somalia 55% 12.1 78,642 35% 7.7 49,641
Sudan 53% 2.9 65,913 35% 1.9 43,155
Yemen 53% 4.0 67,530 35% 2.6 44,213
EUR B & C
Armenia 59% 1.1 907 54% 1.0 834
Azerbaijan 59% 4.7 14,086 35% 2.8 8,329
Georgia 59% 1.7 1,471 54% 1.6 1,352
Kyrgyzstan 59% 3.3 7,922 54% 3.1 7,277
Tajikistan 59% 7.1 24,217 54% 6.5 22,246
Uzbekistan 59% 3.6 41,188 54% 3.3 37,836
Moldova 59% 0.2 159 54% 0.2 146
Ukraine 59% 0.1 590 54% 0.1 542
SEAR B & D
Indonesia 57% 2.3 187,993 54% 2.2 176,588
Korea, Democratic Republic 57% 2.1 12,982 54% 2.0 12,194
Sri Lanka 57% 0.6 3,424 54% 0.6 3,216
Timor Leste 57% 4.3 4,470 54% 4.1 4,199
Bangladesh 55% 3.4 231,585 54% 3.3 225,739
Bhutan 57% 3.8 858 54% 3.6 806
India 53% 3.6 1,777,110 54% 3.7 1,802,809
Myanmar 57% 4.9 79,028 35% 3.0 47,784
Nepal 58% 3.5 52,750 54% 3.2 48,998
WPR B
Cambodia 57% 8.6 63,250 35% 5.2 38,244
Kiribati 57% 4.9 118 54% 4.6 111
Lao People Democratic Republic 57% 4.6 14,067 54% 4.3 13,213
Mongolia 57% 2.6 2,316 54% 2.5 2,176
Papua New Guinea 57% 5.0 16,493 54% 4.7 15,492
Solomon Islands 57% 1.7 493 54% 1.6 463
Viet Nam 58% 0.8 26,089 54% 0.8 24,032
I$ = International dollars; DALY = Disability-adjusted life year; ICER = Incremental cost-effectiveness ratio.
AFR = African Region; EMR = Eastern Mediterranean Region; EUR = European Region; AMR = Region of the Americas; WPR = Western Pacific 
Region; SEAR = South-East Asian Region.
Table 3: Health outcomes of rotavirus vaccination in the GAVI-eligible countries (Continued)Kim et al. BMC Public Health 2010, 10:253
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Figure 2 Distribution of averted rotavirus disease burden (DALYs) in the GAVI-eligible countries. Upper panel shows the distribution of avert-
ed DALYs associated with rotavirus infection by region. Lower panel shows the corresponding distribution by the level of rotavirus mortality burden 
(among children under age 5).
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Table 4: Cost-effectiveness of rotavirus vaccination in the GAVI-eligible countries
Country Base-case vaccine efficacy (adjusted for serotype 
distribution)
Vaccine efficacy based on SAGE recommendation
ICERa (I$/DALY
averted) I$10
per vaccinated
child
ICERa (I$/DALY
averted) I$25
per vaccinated
child
ICERb (I$/DALY
averted) based
on GAVI's co-
financing
scheme
ICERa (I$/DALY
averted) I$10
per vaccinated
child
ICERa (I$/DALY
averted) I$25
per vaccinated
child
ICERb (I$/DALY
averted) based
on GAVI's co-
financing
scheme
AFR D
Angola saving 26 4 0.2 68 22
Benin 25 108 52 57 190 87
Burkina Faso 22 90 37 42 141 59
Cameroon 22 108 57 54 190 93
Chad saving 54 33 17 113 59
Comoros 119 341 150 122 348 153
Ghana 71 221 100 142 398 176
Guinea 18 99 54 49 178 88
Guinea-Bissau 7 68 37 26 113 57
L i b e r i a 1 76 73 23 7 1 1 45 3
Madagascar 20 124 65 60 225 108
M a l i 55 82 92 6 1 0 95 1
Mauritania 21 116 52 58 209 92
N i g e r s a v i n g3 62 31 07 84 2
Nigeria 27 102 48 51 162 74
Sao Thome 40 152 65 83 262 112
Senegal 32 125 56 68 215 95
Sierra Leone 2 41 21 17 79 37
The Gambia 59 196 87 112 328 145
Togo 46 155 75 88 262 121
AFR E
B u r u n d i 2 28 44 44 6 1 4 57 0
Central African 
Republic
20 96 46 50 171 78
Congo 74 250 111 143 422 185
Cote d'Ivoire 21 95 47 44 153 72
Democratic 
Republic of the 
Congo
19 76 39 41 131 62
Eritrea 95 266 117 97 272 120
Ethiopia 28 98 45 55 166 74
Kenya 37 150 68 81 260 115
Lesotho 397 1,061 459 655 1,707 737
Malawi 26 93 40 55 165 71
Mozambique 31 115 48 64 198 83
R w a n d a 15 83 02 3 1 1 45 4
Tanzania 42 147 66 87 258 114
Uganda 31 127 62 68 220 102Kim et al. BMC Public Health 2010, 10:253
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Zambia 23 103 45 49 166 72
Zimbabwe 78 251 110 134 391 170
AMR A, B & D
Cuba 11,332 28,443 12,240 11,909 29,888 12,862
Guyana 4 113 40 7 122 44
Honduras 85 386 190 95 411 201
Bolivia 47 246 120 53 262 128
Haiti 4 105 56 46 212 102
Nicaragua 217 646 289 234 688 307
EMR D
A f g h a n i s t a ns a v i n g4 72 91 59 04 8
Djibouti saving 90 54 25 179 92
Pakistan 42 192 102 95 325 159
S o m a l i a s a v i n g3 93 21 18 35 1
Sudan 84 266 121 148 426 190
Yemen 26 160 82 73 276 132
EUR B & C
Armenia 227 685 312 254 753 341
Azerbaijan saving 95 68 35 223 123
Georgia 131 429 206 148 473 225
Kyrgyzstan 59 215 99 68 239 109
T a j i k i s t a n 68 04 81 09 15 3
Uzbekistan saving 122 58 saving 144 67
Moldova 1,763 4,497 1,949 1,925 4,900 2,122
Ukraine 4,816 12,161 5,243 5,249 13,245 5,710
SEAR B & D
Indonesia 80 302 136 90 326 146
Korea, 
Democratic 
Republic
118 363 154 129 390 165
Sri Lanka 487 1,303 565 522 1,391 603
Timor Leste 41 161 67 46 174 73
Bangladesh 50 209 104 52 216 106
Bhutan 38 175 75 44 190 81
India 54 201 97 53 198 96
Myanmar 28 137 74 75 256 126
Nepal 62 215 102 70 235 110
WPR B
Cambodia saving 44 34 10 111 63
Kiribati 4 111 50 9 122 54
Lao People 
Democratic 
Republic
15 132 77 20 144 83
Mongolia 77 274 114 85 296 123
Papua New 
Guinea
saving 84 36 saving 95 41
Table 4: Cost-effectiveness of rotavirus vaccination in the GAVI-eligible countries (Continued)Kim et al. BMC Public Health 2010, 10:253
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country- or region-specific serotype distribution and
serotype-specific vaccine efficacy. Accordingly, rotavirus
vaccination appeared less cost-effective; for instance,
assuming this alternate efficacy and I$25 per vaccinated
child, only seven countries had an incremental cost per
DALY averted under I$100 (Table 4).
Budget impact: Forecasting disease burden reduction and 
financial costs
Table 5 summarizes the impact of alternative scale-up
scenarios (combined with different vaccine efficacy esti-
mates) on the overall disease burden reduction aggre-
gated across the GAVI countries over a 10-year period.
The first four rows in Table 5 present the results based on
the base-case rollout scenarios. The results from the first
scenario (assuming the base-case rollout scenario, vac-
cine efficacy based on the SAGE approach, and vaccine
immunity waning) show that a 10-year effort for rotavirus
vaccine scale-up would prevent about 41 million cases of
outpatient visits, 4.5 million hospitalizations, and 0.9 mil-
lion deaths caused by rotavirus in the GAVI countries.
Without assuming immunity waning, the second scenario
projects higher levels (~10%) of reduction in disease bur-
den. The other alternative scenarios combined with dif-
ferent assumptions show very similar patterns. Similarly,
Table 6 shows the aggregate financial requirements in the
GAVI countries using the same set of scale-up scenarios.
Figure 3 presents the incremental budget impact for each
year of the 10-year time horizon, using Djibouti as an
example. In our base-case rollout scenario, the country is
assumed to provide rotavirus vaccines starting in 2011
(Table 2), achieve full coverage (89%) in 2015, and main-
tain full coverage for the rest of the time horizon. F or
each year, the left-hand bars in the graph indicate the
financial costs of sustaining a rotavirus program without
considering the savings to the government from averted
treatment costs, while the right-hand bars indicate the
financial costs when including such savings. (See Addi-
tional file 1 for country-specific results not considering
the savings to the government.)
Discussion
While child mortality is reported to have decreased in
general since 1990, mortality among young children
remains high in many developing countries. The most
recent World Health Statistics show that diarrhea makes
up the second or third cause of childhood deaths in most
low-income countries [22]; in 68 of the 72 GAVI-coun-
tries, diarrhea accounts for more than 10% of deaths
among young children. Since rotavirus is the most com-
mon cause of severe gastroenteritis among young chil-
dren, any interventions to control rotavirus infection
have the potential to greatly improve childhood mortality,
contributing to achieving one of the MDG targets.
Our findings show that routine infant vaccination using
either of the two new recent vaccines would prevent 0.9-
2.8 million deaths associated with rotavirus infection
among children under age 5 in the poorest parts of the
world over the next decade (2010-2019), depending on
vaccine scale-up scenarios. Rotavirus vaccination pro-
grams would also prevent 4.5-13.3 million estimated
cases of hospitalization and 41-107 million cases of out-
patient clinic visits in the same population over the same
intervention period.
Our results also show that rotavirus vaccine programs
would be considered a cost-effective public health inter-
vention in most GAVI countries; using the WHO's cost-
effectiveness threshold based on per capita GDP, the vac-
cines were considered cost-effective in 68 of the 72 coun-
tries (~94%). It should be noted that a rotavirus
vaccination program might not prove cost-effective in
countries with a relatively low rotavirus mortality rate
like Cuba, Ukraine, and Moldova. Although the likeli-
hood that a country will introduce a new vaccine or scale-
up rate is not always proportionate to the level of disease
burden, these results may affect policy makers' decisions
whether or not to introduce a vaccine. For example,
although Cuba is classified into a high demand region in a
previous study [36] and in the present study, Cuba's rota-
virus associated mortality rate is less than 1 per 100,000
children under age 5 and estimated incremental cost-
effectiveness is about I$30,000 per DALY averted (at the
Solomon 
Islands
143 444 186 156 476 200
Viet Nam 193 799 390 228 885 427
I$ = International dollars; DALY = Disability-adjusted life year; ICER = Incremental cost-effectiveness ratio.
AFR = African Region; EMR = Eastern Mediterranean Region; EUR = European Region; AMR = Region of the Americas; WPR = Western Pacific 
Region; SEAR = South-East Asian Region.
a ICERs are for a strategy of vaccinating 70% of a single birth cohort born in 2010 assuming a vaccination program cost of I$10 and I$25 per 
vaccinated child compared to no vaccination.
b ICERs are for a strategy of vaccinating 70% of a single birth cohort born in 2010, but vaccination program costs vary across countries according 
to the GAVI's co-financing scheme [32].
Table 4: Cost-effectiveness of rotavirus vaccination in the GAVI-eligible countries (Continued)K im et al. BMC Public Health 2010, 10:253
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Table 5: Health impact of alternative scale-up scenarios in the GAVI-eligible countries
No Scale-up scenarios No. of children 
vaccinated
(in million)
No. of 
outpatient 
visits averted
(r = 0%) (in 
million)
No. of 
hospitalizatio
n averted
(r = 0%) (in 
million)
No. of deaths 
averted
(r = 0%) (in 
million)
YL saved
(r = 3%) (in 
million)
DALYs averted
(r = 3%) (in 
million)
1 Base-case rollout scenario 
(Table 2)
Vaccine efficacy based on 
the SAGE approach
Vaccine immunity waning 
(14% annually)
281.8 40.7 4.5 0.9 20.3 20.4
2 Base-case rollout scenario 
(Table 2)
Vaccine efficacy based on 
the SAGE approach
No vaccine immunity 
waning
281.8 44.1 4.9 1.0 22.0 22.1
3 Base-case rollout scenario 
(Table 2)
Vaccine efficacy adjusted 
for serotype distribution
Vaccine immunity waning 
(14% annually)
281.8 47.8 5.6 1.2 25.3 25.4
4a Base-case rollout scenario 
(Table 2)
Vaccine efficacy adjusted 
for serotype distribution
No vaccine immunity 
waning
281.8 51.7 6.0 1.3 27.3 27.4
5 (Modified) Wolfson et al. 
scenario [37]
Vaccine efficacy based on 
the SAGE approach
No vaccine immunity 
waning
410.5 64.2 7.7 1.6 35.6 35.7
6 (Modified) Wolfson et al. 
scenario [37]
Vaccine efficacy adjusted 
for serotype distribution
No vaccine immunity 
waning
410.5 81.4 10.4 2.2 48.1 48.3
7 A flat coverage of 70%
Vaccine efficacy based on 
the SAGE approach
No vaccine immunity 
waning
537.0 85.9 10.1 2.1 48.9 49.1
Kim et al. BMC Public Health 2010, 10:253
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8 A flat coverage of 70%
Vaccine efficacy adjusted 
for serotype distribution
No vaccine immunity 
waning
537.0 106.6 13.3 2.8 64.5 64.7
r = discount rate; YL = years of life; DALYs = disability-adjusted life-years; I$ = international dollars; SAGE = Strategic Advisory Group of Experts 
on Immunization.
a Base-case analysis.
Table 5: Health impact of alternative scale-up scenarios in the GAVI-eligible countries (Continued)
Table 6: Budget impact of alternative scale-up scenarios in the GAVI-eligible countries
Financial costsa
No Scale-up scenarios No. of children 
vaccinated
Global society 
perspective 
(Total 
vaccination 
program costs)
GAVI Alliance 
perspective 
(Vaccine cost 
support)
Local 
government 
perspective (not 
including 
medical cost 
savings)b
Local 
government 
perspective 
(including 
medical cost 
savings)b
(in million) (US$, million) (US$, million) (US$, million) (US$, million)
1 Base-case rollout scenario 
(Table 2)
Vaccine efficacy based on the 
SAGE approach
Vaccine immunity waning 
(14% annually)
281.8 5,879 4,079 1,800 1,714
2 Base-case rollout scenario 
(Table 2)
Vaccine efficacy based on the 
SAGE approach
No vaccine immunity waning 281.8 5,879 4,079 1,800 1,707
3 Base-case rollout scenario 
(Table 2)
Vaccine efficacy adjusted for 
serotype distribution
Vaccine immunity waning 
(14% annually)
281.8 5,879 4,079 1,800 1,695
4c Base-case rollout scenario 
(Table 2)
Vaccine efficacy adjusted for 
serotype distribution
No vaccine immunity waning 281.8 5,879 4,079 1,800 1,686
5 (Modified) Wolfson et al. 
scenario [30]
Vaccine efficacy based on the 
SAGE approach
No vaccine immunity waning 410.5 8,573 5,943 2,630 2,472Kim et al. BMC Public Health 2010, 10:253
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composite vaccination cost of I$25 per vaccinated child).
It is conceivable that policy makers might want to con-
sider using resources to introduce other childhood vac-
cines or to extend coverage of existing health
interventions that target a higher burden of disease.
In the present analysis, the most influential factor in the
cost-effectiveness results was per child vaccination costs,
which includes rotavirus vaccine costs, vaccine wastage,
and any activities to support the delivery of the vaccines.
Since the data on country-specific incremental costs for
introducing a new childhood vaccine into a national
immunization program are rarely available for low-
income countries, we chose to use a composite cost
approach, assuming a total program cost of I$10 or I$25
per vaccinated child. Accordingly, our base-case cost-
effectiveness results use standardized vaccination pro-
gram costs across the 72 GAVI countries, so the main dif-
ferences in the incremental cost-effectiveness ratios may
be attributable to the differences in disease burden (i.e.,
rotavirus associated mortality rates, ratios of rotavirus
associated hospitalizations or outpatient visits to rotavi-
rus deaths) and vaccine efficacy adjusted for serotype dis-
tributions. Note that, although the discount rate was still
relatively influential, it was not as important as it is with
vaccines where benefits are realized in the distant future
(e.g., HPV or HBV vaccines). The results were robust to
country-specific hourly wage rates or transportation
costs per medical visit, which were used in calculating
direct non-medical costs such as caregivers' time costs or
travel costs. The results were not sensitive to assumptions
about medical utilization such as average length of hospi-
talization or average time spent per outpatient clinic visit.
Note that our base-case estimates of the main health
outcome (i.e. DALYs averted) are based on uniform age
weights (K = 0), primarily for normative reasons, while a
majority of previous similar studies use the standard age
weights (K = 1) used by the WHO GBD study [19]. Uni-
form age weighting leads to relatively lower years of life
lost (YLL) compared with those associated with standard
age weighting (K = 1) over the age range of age 0-4 years
[20]. Accordingly, when assuming similar model struc-
ture and parameter values, our results are more conserva-
tive since our base-case analysis (K = 0) yields a lower
number of DALYs averted than other similar studies that
evaluate the impact of rotavirus vaccination in terms of
DALYs incorporating non-uniform age weights (K = 1)
(as also shown in the sensitivity analysis results).
Although the WHO SAGE recommended global use of
rotavirus vaccines based on the evidence from recent
clinical trials, there is a high level of uncertainty about
short-term and longer-term vaccine efficacy in local set-
tings given the variability of rotavirus serotype distribu-
tions across regions and over time. Our analysis shows
the implication of following SAGE's recommendation to
transfer vaccine efficacy by using data from other coun-
tries with comparable levels of childhood mortality. In a
m a j o r i t y  o f  t h e  G A V I  c o u n t r i e s ,  t h e  e x t e n d e d  v a c c i n e
efficacy following the SAGE approach was lower than the
weighted average of serotype-specific vaccine efficacy
used in our base-case analysis. Correspondingly, the
6( M o d i f i e d )  W o l f s o n  e t  a l .  
scenario [30]
Vaccine efficacy adjusted for 
serotype distribution
No vaccine immunity waning 410.5 8,573 5,943 2,630 2,414
7 A flat coverage of 70%
Vaccine efficacy based on the 
SAGE approach
No vaccine immunity waning 537.0 11,222 7,785 3,437 3,236
8 A flat coverage of 70%
Vaccine efficacy adjusted for 
serotype distribution
No vaccine immunity waning 537.0 11,222 7,785 3,437 3,170
r = discount rate; YL = years of life; DALYs = disability-adjusted life-years; I$ = international dollars; SAGE = Strategic Advisory Group of Experts 
on Immunization.
a All 10-year forecasts are based on the composite program cost of I$25 (corresponding to US$5 per vaccine dose) per vaccinated child and are 
not discounted.
b The vaccine costs to local governments are based on the GAVI's co-financing scheme [32].
c Base-case analysis.
Table 6: Budget impact of alternative scale-up scenarios in the GAVI-eligible countries (Continued)Kim et al. BMC Public Health 2010, 10:253
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results of a secondary analysis using the SAGE approach
showed the estimated avertable burden to be about 30%
(0-70%) lower.
Recently an increasing number of published studies
have evaluated the health and economic consequences of
rotavirus vaccines in different settings, using various
modeling approaches [16,25,26,36,39-59]. Ten studies
[16,25,36,39-44,52] have assessed cost-effectiveness of
rotavirus vaccination in low-income countries. When
subject to the same currency type, inflation and vaccine
price, our results were comparable to those from the
studies performed in low-income country settings. For
example, when we roughly adjusted Rose et al.'s results
for India that are obtained using an individual-level
Markov model [39] for currency type and inflation, the
adjusted incremental cost-effectiveness ratio of ~I$140
per DALY averted was comparable to our result for India,
I$200 per DALY averted (at I$25 per vaccinated child).
When we assumed similar program costs, the discrep-
ancy in the two studies' results was further reduced.
The cost-effectiveness profiles of rotavirus vaccines
from the present study are also very similar to those for
HPV vaccines reported in a previous study [60], which
was performed using a similar approach in the 72 GAVI-
eligible countries. That study reported that at a cost per
vaccinated girl of I$10 ($2 per dose), for 49 of 72 coun-
tries, the cost per DALY averted was less than I$100 (or
the program was cost-saving), and for an additional 12
countries, less than I$200. At higher costs per vaccinated
girl (e.g. I$25), for 33 of 72 countries, the cost per DALY
averted was less than I$300, and for an additional 23
countries, less than I$500 [60]. However, provided vac-
cine prices are similar, the financial resources required
are very different, in large part due to differences in the
size of the target populations (i.e., infants of both genders
versus adolescent girls). Interestingly, although not
immediately intuitive, the avertable mortality burden
from the two vaccines is also similar. For example, while
annual deaths among the 72 GAVI countries are esti-
mated to be ~466,000 from rotavirus [29] and ~161,000
from cervical cancer [61], if we restrict the comparison to
female gender, the annual deaths are ~230,000 versus
~161,000. Further, these estimates represent deaths based
on a snapshot of a population structure for a particular
calendar year, and do not reflect a future population
dynamics. Consider the present day (2010) cohort of
newborn infants and the present day cohort of 9-year old
girls (2010) in the GAVI-eligible countries. Modeled pro-
jections show approximately 508,000 of the infants will
die from rotavirus and 580,000 of the 9-year old girls will
Figure 3 Budget impact of rotavirus vaccination in Djibouti. This figure shows the budget impact of a rotavirus program in Djibouti for each year 
of a 10-year time horizon. For each year, the difference between the bars indicates the savings to the government from averted treatment costs.
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eventually die from cervical cancer. Clearly both vaccines
are priorities.
Although a rotavirus program proves cost-effective
over a wide range of parameter values and alternative
assumptions, countries need information on affordability
of the vaccines as well. That is, in most low-income coun-
t r i e s  w i t h  s e v e r e  r e s o u r c e  c o n s t r a i n t s ,  m u l t i p l e  p u b l i c
health priorities compete for a limited shared budget;
policy makers need to know the financial costs required
to implement any program as well as its value for money.
In the present study, in addition to the secondary cost-
effectiveness analysis from the local government perspec-
tive, we performed a budget impact analysis based on
simplifying assumptions, taking into account the 'new
vaccine co-financing policy' recently announced by the
GAVI Alliance, in order to project financial requirements
and potential savings from averted medical costs for each
year of the 10-year period. Our findings suggest that, with
GAVI's support, the costs to each GAVI country would be
reduced to approximately I$10-I$11 when assuming a
composite program cost of I$25, but that covering this
would still be a substantial burden to the lowest-income
GAVI countries. This type of analysis may be useful to
policy makers seeking to address the question of afford-
ability of new vaccines by comparing the budget impact
forecast with their own projected total immunization
budget. Assessment of affordability is not complicated
when there is a single earmarked budget for a new vac-
cine of interest. However, if there are multiple other
immunization (or public health) programs competing for
a shared budget, choosing an optimal set of immuniza-
tion programs under a budget constraint can be challeng-
ing. Recently there have been a number of studies aiming
to help policy makers with resource allocation, taking
into account multiple criteria such as ethical or political
considerations in addition to technical efficiency [62-65].
Note that the results of our financial forecasting and
overall disease burden reduction are, of course, sensitive
to the forecasted level of demand for rotavirus vaccine.
We base our base-case scale-up scenario on local experi-
ence with other childhood vaccines and national income
levels. However, there are reasons why this forecast may
be over- or under-estimated. For instance, there may be
discrepancies between reported and actual uptake rates
in local settings simply due to the challenges of collecting
health information across entire populations. Further,
while we assumed that all children covered would receive
a full 3 doses of vaccine, in practice dose completion rates
may vary, affecting the total cost and altering cost-effec-
tiveness (due to both changes in cost and changes in
impact if vaccine efficacy with fewer than 3 doses is lower
than that under a full 3-dose course). Thus, to come up
with more reliable forecasts for financial requirements
associated with new vaccine introduction, more research
is needed to improve the quality of coverage data and to
conceptualize an approach to forecasting future uptake
rate more realistically. Also, some operational research is
needed to identify factors that might affect the sustain-
ability of scale-up scenarios.
Our study has several limitations. First, we synthesized
available data using an Excel-based model that relies on
simplifying assumptions; this was a purposeful tradeoff in
that, unlike our past detailed models of a single country
[16], here we sought to provide a broad perspective on
avertable burden and cost-effectiveness of a global invest-
ment to vaccinate children against rotavirus. As such, this
simple model cannot capture indirect effects that might
result from a large-scale routine immunization program.
If a rotavirus program can provide such benefits among
non-vaccinated subpopulations, as suggested in recent
published studies that used a dynamic mathematical
model to estimate the cost-effectiveness of rotavirus vac-
cines in the United States [58,66], we may be underesti-
mating benefits. Second, unlike our previously published
model applied to a single country [16], this static model
applied to 72 countries is implicitly based on a decision-
tree structure, and thus has a limited capacity to explore
uncertainty surrounding natural history of rotavirus
infection and potential serotype replacement that might
occur in the long term after vaccine introduction [17,67].
Third, our analysis assumes composite costs rather than
estimating individual country-specific vaccine delivery
costs. Accordingly, our results should be carefully inter-
preted by donors or global policy makers interested in the
relative cost-effectiveness of the rotavirus vaccines condi-
tional on alternative strategies to achieve coverage. We
emphasize the need for future research to estimate the
incremental costs of delivering new rotavirus vaccines in
local settings. Lastly, while we tried to estimate country-
specific data for the ratios of hospitalizations and outpa-
tient visits to deaths and for serotype distributions of
rotavirus, country-specific data were often not available,
leaving us to use data from neighboring countries or
regional average.
Conclusion
The limitations of our study suggest that our findings
should be considered for only what they are intended-
broad estimate of the potential impact and value of rota-
virus vaccination. Our main findings suggest that rotavi-
rus vaccine introduction would be considered a
worthwhile investment for improving general develop-
ment as well as public health level in most low-income
countries, with a favorable cost-effectiveness profile even
under a vaccine price ($1.5-$5.0 per dose) higher than
those of traditional childhood vaccines. In addition, our
study provides information on an approximate future
stream of financial costs that need to be included inKim et al. BMC Public Health 2010, 10:253
http://www.biomedcentral.com/1471-2458/10/253
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health budgets. Further, as more evidence on vaccine effi-
cacy and safety, particularly associated with vaccination
schedule in local settings [68], and more country-specific
data (e.g., data from the cMYP immunization financing
database) become available, our analysis can serve as
baseline for any future refinement of country-specific
results.
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